Halberd (Halberd) EV-to-EBIT : (As of Jun. 15, 2024)

View and export this data going back to 2009. Start your Free Trial

What is Halberd EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Halberd's Enterprise Value is $5.55 Mil. Halberd does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in Jul. 2023. Therefore, GuruFocus does not calculate Halberd's EV-to-EBIT at this moment.

The historical rank and industry rank for Halberd's EV-to-EBIT or its related term are showing as below:

HALB' s EV-to-EBIT Range Over the Past 10 Years
Min: -13.69 Med: 0 Max: 0
Current: -12.41

HALB's EV-to-EBIT is ranked worse than
100% of 422 companies
in the Biotechnology industry
Industry Median: 9.705 vs HALB: -12.41

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Halberd's Enterprise Value for the quarter that ended in Jul. 2023 was $5.63 Mil. Halberd does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in Jul. 2023. Therefore, GuruFocus does not calculate Halberd's Earnings Yield (Joel Greenblatt) % at this moment.

Halberd EV-to-EBIT Historical Data

The historical data trend for Halberd's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Halberd EV-to-EBIT Chart

Halberd Annual Data

Trend

Jul08

Jul22

Jul23

EV-to-EBIT

-4.04

-12.60

Halberd Semi-Annual Data
	Jul08	Jul22	Jul23
EV-to-EBIT	-	-4.04	-12.60

Competitive Comparison of Halberd's EV-to-EBIT

For the Biotechnology subindustry, Halberd's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Halberd's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Halberd's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Halberd's EV-to-EBIT falls into.

Halberd EV-to-EBIT Calculation

Halberd's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	5.549	/
	=

Halberd (OTCPK:HALB) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Halberd's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jul. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jul. 2023 )	=	EBIT	/	Enterprise Value (Q: Jul. 2023 )
	=		/	5.6329875
	=	%

Halberd EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Halberd's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Halberd (Halberd) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halberd Corp (OTCPK:HALB) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

P.O. Box 25, Jackson Center, PA, USA, 16133

Website

https://www.halberdcorporation.com

Halberd Corp is a research-based biotechnology company seeking to discover and develop medical treatments for a range of diseases. The Company's extracorporeal treatment is designed to treat hard-to-cure blood-borne, neurologic and infectious diseases. The Company's patented methodology removes the appropriate bodily fluid from the patient, in a continuous fashion, like dialysis, or in a batch process, like blood sample testing.

Executives

John Christopher Maddox	director, 10 percent owner, officer: President, COO, Treasurer and, other: Interim CFO	10755 VERNON, HUNTINGTON WOODS MI 48070
Mark Sven Lundquist	director, 10 percent owner, officer: CEO, Secretary and Director	24655 TUDOR LANE, FRANKLIN MI 48025
Cocco Nicholas A. Jr.	director	50104 N. JIMMY COURT, CHESTERFIELD MI 48047-1898
Leland Michael Thomas	director	280 LASALLE PLACE, GROSSE POINTE FARMS MI 88236